Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Seagen Inc. is a biotechnology company that discovers, develops, and commercializes targeted therapies to treat cancer. A leader in antibody-drug conjugate (ADC) technology, Seagen has developed multiple approved medicines revolutionizing cancer care. Key products include ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin), TUKYSA® (tucatinib), and TIVDAK® (tisotumab vedotin). Founded in 1997 as Seattle Genetics and renamed Seagen in 2020, the company has built a strong pipeline of innovative cancer treatments. In December 2023, Pfizer successfully completed its acquisition of Seagen for $43 billion, aiming to significantly accelerate Pfizer's efforts in oncology and leverage Seagen's ADC expertise. Seagen's operations are now being integrated into Pfizer's oncology division.
The Bothell campus served as the central hub for Seagen's research and development, corporate operations, and administrative functions.
The campus features state-of-the-art laboratory facilities designed for advanced biotechnology research, particularly in antibody-drug conjugate (ADC) development and manufacturing process development.
Seagen was known for its innovative, science-driven, and patient-focused work culture. Employees often described it as a collaborative environment dedicated to making a significant impact in oncology.
The Bothell headquarters was instrumental in Seagen's growth and success, serving as the birthplace for many of its groundbreaking cancer therapies and ADC platform technologies.
Prior to its acquisition by Pfizer, Seagen established a significant global presence focused on the research, development, and commercialization of its cancer therapies. This included R&D facilities in the US, an international headquarters in Switzerland to manage European and ex-US operations, and a commercial footprint in multiple countries. Its therapies reached patients worldwide through direct sales and partnerships. Post-acquisition, Seagen's global reach and functions are being integrated into Pfizer's extensive worldwide oncology operations.
21823 30th Dr SE
Bothell
WA
USA
Address: Seagen International GmbH, Theilerstrasse 1a, CH-6300 Zug, Switzerland
Manages and supports Seagen's (now Pfizer's) product commercialization and clinical development activities across Europe and other international markets.
Address: 1 Tower Place, South San Francisco, CA 94080, USA
Focuses on discovery research, translational science, and early-stage clinical development to expand the oncology pipeline.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Seagen' leadership includes:
Seagen has been backed by several prominent investors over the years, including:
The most significant executive changes at Seagen in the last 12 months were driven by its acquisition by Pfizer, completed in December 2023. This led to the departure or role changes for most of Seagen's top leadership as operations began integrating into Pfizer's oncology division. Pfizer appointed its own leadership to head the combined oncology organization.
Discover the tools Seagen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Seagen, like many corporations, utilized standardized email formats. The most common formats included first initial followed by last name (e.g., jdoe@seagen.com) or first name dot last name (e.g., jane.doe@seagen.com). Post-Pfizer acquisition, communications may transition to Pfizer's email systems for integrated employees.
[first_initial][last]@seagen.com
Format
jdoe@seagen.com
Example
85%
Success rate
Pfizer News • December 14, 2023
Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc. for $229 per share in cash, totaling $43 billion. This strategic move is expected to significantly bolster Pfizer's oncology portfolio and capabilities, particularly in antibody-drug conjugates....more
Pfizer News • February 28, 2024
The U.S. FDA approved PADCEV in combination with KEYTRUDA for patients with locally advanced or metastatic urothelial cancer. This approval converts the accelerated approval to full approval and expands the indication. PADCEV was originally developed by Seagen and Astellas....more
Seagen News (archived) • October 2, 2023
Seagen Inc. and Genmab A/S announced that the U.S. FDA granted full approval for TIVDAK® for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This converted the earlier accelerated approval to full approval....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Seagen, are just a search away.